CD8A and neoplasm: Given that the previous pseudotime analysis suggested that the tumor-rejecting CD8_Tex with effector function and cytolytic capacity from the LR-DPVB-treated tumor evolved from CD8_Tpex (Fig. 3e, f, Supplementary Fig. 6c), we further explored whether intratumoral stem-like CD8+ Tpex could enhance the antitumor effect of DPVB using the stem-like CD8+ Tpex transfer mouse model in vivo (Fig. 4d).